Estrogen accelerates the resolution of inflammation in macrophagic cells

Alessandro Villa, Nicoletta Rizzi, Elisabetta Vegeto, Paolo Ciana & Adriana Maggi

Although 17β-estradiol (E2) anti-inflammatory activity has been well described, very little is known about the effects of this hormone on the resolution phase of the inflammatory process. Here, we identified a previously unreported ERα-mediated effect of E2 on the inflammatory machinery. The study showed that the activation of the intracellular estrogen receptor shortens the LPS-induced pro-inflammatory phase and, by influencing the intrinsic and extrinsic programs, triggers the resolution of inflammation in RAW 264.7 cells. Through the regulation of the SOCS3 and STAT3 signaling pathways, E2 facilitates the progression of the inflammatory process toward the IL10-dependent “acquired deactivation” phenotype, which is responsible for tissue remodeling and the restoration of homeostatic conditions. The present study may provide an explanation for increased susceptibility to chronic inflammatory diseases in women after menopause, and it suggests novel anti-inflammatory treatments for such disorders.

The hypothesis that estrogens may play a role in protection against chronic inflammatory diseases stems from a large body of clinical and preclinical evidence that has demonstrated that a) the etiology and course of chronic inflammatory diseases is influenced by the menstrual cycle and pregnancy1–3; b) a significant increase in the incidence of disorders characterized by a strong inflammatory component (e.g., osteoporosis, atherosclerosis, diabetes and other metabolic diseases, arthritis and others) is a hallmark of the cessation of ovarian functions4; and c) fertile female mammals are less prone than males to these diseases5–6. Indeed, circulating estrogens were shown to target cells of monocyte lineage and to mitigate several of the aspects of the native immune response. Our prior results in rodent cells showed that macrophages express the classical intracellular receptors α and β (ERα and ERβ)7. In addition, other authors demonstrated that also the membrane-bound G-protein-coupled estrogen receptor (GPR30/GPER-1) is expressed in murine macrophages8. The ERα-bound estrogen was shown to decrease the synthesis of pro-inflammatory compounds9,10, to control mitochondrial mitosis11 and respiratory function12, to induce the degradation of damaged proteins through the proteasome13, and to diminish monocyte apoptosis and activation of hypoxic genes14. At a molecular level, the hormone-activated ERα was shown to impair NF-κB transcripitional activity by preventing its nuclear translocation in the presence of strong inflammatory stimuli (such as lipopolysaccharide, LPS). In this case, the estrogen-dependent prevention of NF-κB activation did not require de novo protein synthesis to modify IκBα degradation, and it occurred through a direct interaction between the hormone-activated ERα and phosphatidylinositol 3-kinaseα15. In fact, the intracellular ERα and ERβ, in addition to acting as hormonally regulated transcription factors, may also interact with cytoplasmic and nuclear proteins responsible for signal transduction and interfere with their functions15. Recent studies have suggested that, in addition to intracellular receptors, the membrane-bound GPR30 receptor may be involved in estrogen anti-inflammatory action by pinpointing GPR30-specific agonists that regulate the expression of the cell-surface of Toll-like receptor 4 (TLR4) in macrophages8. Monocytes/macrophages are exceptionally plastic cells able to adopt the context-specific phenotypes necessary to protect the host from harmful events and to reestablish tissue homeostasis when
the inflammatory reaction is over. This is achieved with significant changes in the transcriptome and proteome: inflammatory stimuli (derived from microbes, damaged tissues or activated lymphocytes) induce macrophages to acquire the pro-inflammatory polarization or M1 consisting of the rapid activation of NF-κB and the synthesis and secretion of pro-inflammatory cytokines (e.g., TNFα, IL1β, IL6, II12, and IL23) and chemokines (particularly monocyte chemotactic protein-1, MCP1). These inflammatory compounds are responsible for the increased expression of cytotoxic mediators such as inducible nitric oxide synthase (iNOS). They are also responsible for increased expression of enzymes relevant for the phagocytosis of damaged tissues or microorganisms and for the migration and further recruitment of macrophages. This sequela of events aimed at the rapid and efficient removal of the inflammatory stimuli is often the cause of severe damage at the site of inflammation; thus, a well-balanced immune response ends with the repair and functional recovery of all damaged tissues. This “resolution phase” is carried out by macrophages in concert with the host tissue and other immune cells as lymphocytes and occurs by acquiring the conventionally named alternative activation (AA) state or M2a polarization25 in which macrophages further prompt the synthesis and secretion of specific anti-inflammatory cytokines (mainly IL4 and IL13) by T lymphocytes to finally repress the production of pro-inflammatory cytokines (like TNFα, IL12, and IL1β) and iNOS. Recent studies have shown that macrophages may also activate an intrinsic program that converts them to the anti-inflammatory phenotype17. The dampening of the inflammatory response is associated with the “acquired deactivation” (AD) or M2c phenotype, characterized by the production of IL10 and TGFβ16, compounds responsible for the restoration of tissue homeostasis through the repair of damaged cells, cell proliferation, restructuring of the connective tissue and angiogenesis.

Unexplored so far is whether estrogen anti-inflammatory activity is extended to this second phase of the native inflammatory reaction. The aim of our study was to evaluate the extent to which estrogens participate in the intrinsic or T-cell-regulated resolution of the macrophage pro-inflammatory polarization stage. The study shows that estrogens interact with the signaling responsible for the onset of the resolution phase and are able to shorten the duration of the pro-inflammatory stage and to direct the resolution of the inflammation toward the acquired deactivation stage. These findings may be relevant particularly for the identification of novel estrogen receptor modulators efficacious in the prevention or mitigation of chronic inflammation.

**Results**

7β-estradiol (E2) opposes interleukin 4 (IL4) induced alternative activation in macrophages. IL4 has been described as one of the principal mediators of the transition of macrophages toward the resolution stage of inflammation. We therefore investigated the potential involvement of estrogens in the response of the mouse leukemic cell line RAW 264.7 of monocyte lineage to IL4. In our experimental paradigm, cells were stimulated at time 0 with 20 ng/ml IL4 alone or in the presence of 5 nM E2, and then harvested every hour in the following 8 h to measure the content of mRNA encoding arginase 1 (ARG1), an well-established marker of the AA. The results in Fig. 1a indicate that the cells responded quite rapidly to IL4 stimulation alone. Five hours after treatment with the cytokines, the content of Arg1 mRNA was 292-fold higher than at time 0 and in the control, untreated cells (not shown). In the cells incubated with IL4 and E2, the response was significantly reduced, and at 5 h, the concentration of Arg1 mRNA measured was approximately half (58%) with respect to the cells stimulated with IL4 only. Similar results were observed with another AA marker, Ch31, or Ym1 (Supplementary Fig. S1a). In further experiments, harvesting the cells 5 h after treatment showed that E2 inhibition of the response to IL4 was antagonized efficiently by co-incubation with the high affinity, specific antagonist of intracellular ERs ICI 182,780 (Fulvestrant) at a 250 nM concentration. At this concentration ICI 182,780 alone did not affect Arg1 expression (not shown). The antagonism by ICI 182,780 demonstrated the involvement of ERα in the E2 interference of IL4-driven expression of the AA polarization marker (Fig. 1b). These results were confirmed using another macrophage cell line, J774A.1 (as shown in Supplementary Fig. S1b–e), suggesting that these findings were not restricted to RAW264.7. Measurement of ERα (Esr1) and ERβ (Esr2) mRNA showed that the expression of the ERα isoform is predominant in this cell line (Supplementary Fig. S2a). The expression of ERα in RAW cells was also assessed by means of immunocytochemistry and confocal microscopy, showing that ERα protein accumulates in the nuclear compartment following the treatment with 5 nM E2 (Supplementary Fig. S2d). All together, these results led us to conclude that the E2 interference of IL4 activity had to be ascribed to the liganded ERα.

**STAT 6 is not a direct target of estrogen activity.** Several authors showed that the IL4 receptor (IL4R) couples with the Signal Transducer and Activator of Transcription 6 (STAT6) and activates the transcriptions of several genes, including the Arg118. To verify whether the E2 effect on the accumulation of Arg1 mRNA induced by IL4 was associated with an interference of the E2-ER complex with STAT6 signaling, we studied the effect of E2 in cells treated with the small molecule selective inhibitor of STAT6, AS 1517499. The blockage of STAT6 activity confirmed the major role played by STAT6 in the IL4 signal transduction because, in the presence of AS 1517499, no significant induction of the Arg1 gene expression was observed after IL4 treatment. Nevertheless, AS 1517499 produced a paradox effect in cells treated with IL4 and E2 combined; in this case, E2 not only failed to reduce but actually significantly increased Arg1 mRNA (119-fold induction) (Fig. 1c). The observation that this latter induction was not
antagonized by ICI 182,780 led us to hypothesize the contribution of an ERα-independent pathway and to investigate the involvement of an alternative mediator of E2 action, the transmembrane receptor.

Figure 1. IL4 induced production of Arg1 mRNA is regulated by estrogens in Raw 264.7 cells. (a) Time-course of Arg1 mRNA accumulation after IL4. RAW 264.7 were treated with 20 ng/ml recombinant mouse interleukin 4 (IL4, dashed line) alone or with 5 nM 17β-estradiol (IL4+E2, continuous line). mRNA cell content was measured by quantitative RT-PCR and data are expressed as $2^{-\Delta\Delta C_t}$ using the 36B4 transcript as an internal reference standard. Dots represent mean ± s.e.m. of three experiments done in triplicate, **$P < 0.01$; ***$P < 0.001$ by unpaired t-test. (b,c) Arg1 mRNA was measured in cells treated for 5 hours with IL4 (20 ng/ml), E2 (5 nM), ICI 182,780 (250 nM), AS1517499 (1 μg/mL); data were calculated and are expressed as in the previous panel. Bars represent the mean ± s.e.m. of 6 experiments done in triplicate. *$P < 0.05$; **$P < 0.01$; ***$P < 0.001$ by two-way ANOVA versus control. §§$P < 0.01$ by two-way ANOVA versus IL4. §§§$P < 0.01$ by two-way ANOVA.

Scientific Reports | 5:15224 | DOI: 10.1038/srep15224
GPR30, expressed in RAW 264.7 cells at a high concentration\textsuperscript{19}. Figure 2a shows that the specific agonist of GPR30, G1 (5 nM), did not antagonize the induction of Arg1 mRNA by IL4 and the addition to the medium of ICI 182,780 did not have any influence on Arg1 mRNA expression. This result was expected because the compound is not an antagonist of GPR30\textsuperscript{20}. G1 was per se devoid of any effect on Arg1 basal expression (not shown). Conversely, in the presence of AS 1517499, the exposure to IL4 + G1 led to an increase of Arg1 mRNA superimposable with the effect of IL4 + E\textsubscript{2} (Fig. 2b), and such increase was not modulated by ICI 182,780. Moreover, the treatment with the GPR30 specific agonist G15 abolished the effect of IL4 + E\textsubscript{2} and IL4 + G1 on Arg1 mRNA in the presence of AS 1517499 (Supplementary Fig. S3). Taken together, these results suggested that GPR30 was accountable for the STAT6-independent induction of Arg1 expression previously observed following treatment with E\textsubscript{2}. This hypothesis was supported by the observed effects of the different treatments on the phosphorylation of AKT, a target of PI3K involved in the intracellular signaling of GPR30\textsuperscript{1}. In the absence of STAT6 inhibitor (Fig. 2c), G1 did not
further affect the increased phosphorylation of AKT induced by IL4 (+190%); however, in the presence of AS 1517499, both E2 and G1 had a significant effect on pAKT accumulation which, compared to IL4 alone, was highly increased (+84%). This effect was not blocked by ICI 182,780 (Fig. 2d). Blockade of AKT phosphorylation was observed in the presence of the selective inhibitor of PI3K, LY294002. No changes were observed in total AKT content. These results pointed to a complex interplay between IL4 and E2 in the RAW 264.7 cells, thus suggesting a significant role of the hormone in the induction of the resolution phase in this cell line.

**IL4 up-regulates the expression of ERα.** Next, we investigated the extent to which the expression of ERα, ERβ and GPR30 were sensitive to IL4R activation (Supplementary Fig. S2a). QPCR showed that, at the C, selected for the relative measure of the concentration of ERα and GPR30 (Gper1) mRNA, no ERβ3 amplicon fluorescence was observed and Gper1 mRNA content was 227% higher than ERα mRNA; however, ERα mRNA was significantly increased (+180%) after IL4 treatment and reached an intracellular concentration comparable to Gper1. Treatment with E2 and ICI 182,780 did not further change ERα mRNA content. None of the treatments had a significant effect on Gper1 mRNA. Similarly, when we measured ERα protein content (Supplementary Fig. S2b), we observed a significant increase of ERα in the presence of IL4 (+136%). When E2 and/or ICI 182,780 were tested in combination with IL4, E2 did not influence its receptor content, which was decreased in the presence of ICI 182,780. This latter observation was in line with previous reports on the ability of ICI 182,780 to increase ERα protein turnover22. AS 1517499 prevention of ERα up-regulation by IL4 indicated the requirement of STAT6 to increase the ERα gene expression (Supplementary Fig. S2c).

These results provided a potential explanation for the opposite effects of E2 on IL4-induced Arg1 expression: in the presence of a functional STAT6 pathway, ERα content was significantly increased by IL4, leading E2 to act predominantly through ERα, which limited the expression of the M2 marker. When STAT6 was inhibited, IL4 treatment was not followed by the up-regulation of ERα and E2 preferred signaling pathways through GPR30, which conceivably had a positive effect on Arg1 transcription.

**Mechanism of E2-ERα inhibition of IL4-dependent activation of Arg1 transcription.** In several cells, including RAW 264.7, prior studies showed that the E2-ERα complex may directly increase the expression of the suppressor of cytokine signaling 3 (SOCS3)23 and an ERα motif was found at -1493–1489 nt upstream of the Socs3 start site24. SOCS are a family of proteins that are highly relevant for the negative feedback that regulates cytokine signal transduction25. In macrophages, IL4 was described to decrease Socs3 mRNA and protein concentrations26 in association with the increase of Arg1 expression27, and in AA/AD-activated macrophages, the expression of SOCS1 is critical for the Arg1-induced anti-inflammatory response28. A time course study showed that IL4 did not alter Socs3 expression profile which was significantly increased by IL4+E2 starting from 2 h after exposure to the hormone. The highest concentration of Socs3 was reached at 5 h, and remained unchanged up to 8 h (Fig. 3a). Treatment with E2 alone at 5 h did not cause any change in SOCS3 expression. This is in contrast with prior reports23, likely because of the very high concentration of E2 used by Liang et al. (20-fold higher). SOCS3 expression was massively induced by IL4+E2 treatment, as SOCS3 mRNA and protein increased 119-fold and 30-fold, respectively (Fig. 3c,d). The effect of the sex hormone was blocked by ICI 182,780 and by the inhibition of the STAT6 pathway with the AS 1517499 compound (Fig. 3e,f). We also studied Socs1 mRNA expression, which was increased after the treatment with IL4 only, while the combined treatments with IL4+E2, IL4+E2+ICI, and IL4+G1 blocked IL4 activity on the gene (Supplementary Fig. S4). Thus, E2, unable to modulate SOCS3 in unstimulated RAW 246.7, caused a major production of SOCS3 mRNA and protein in the presence of IL4. The blockage of such an effect by ICI 182,780 suggested the implication of ERα. The observation that STAT6 inhibitor prevented any E2-dependent increase of SOCS3 mRNA and protein provided further support for the hypothesis that, in the presence of IL4, E2 preferential signaling was via ERα.

We also verified whether other pathways could be involved in E2 inhibition of IL4-induced Arg1 synthesis. Prior studies in tumor cells showed that ERα may cross-couple with the JAK/STAT3 pathways28. Indeed, Supplementary Figure S5 shows that, in RAW 264.7 cells, the phosphorylated form of STAT3 was slightly increased by IL4 (1.4-fold versus controls), possibly because pSTAT3 expression was already quite high prior treatments. When IL4 was combined with E2, the pSTAT3 was two-fold higher than in controls, and such an effect was antagonized by ICI 182,780. STAT3 is known to regulate the expression of genes involved in the resolution phase of inflammation, such as Il10. We therefore tested whether the effect of estrogens was associated with an induction of this cytokine. Figure 3b shows a time-dependent induction of Il10 only in cells treated with IL4+E2. Figure 3g,h confirm that E2 was indeed able to induce Il10 mRNA when administered in the presence of IL4. The observation that ICI 182,780 and AS 1517499 blocked the effect of the hormone suggested that its action occurred via the ERα and required fully functional IL4R signaling.

All together, these data demonstrated that E2, by modulating the effect of IL4 signaling, had the potential to interfere with the resolution phase driven by T lymphocytes.

Studies in wound-healing and in primary macrophage cells have clearly shown that macrophages have intrinsic mechanisms for the conversion from the pro-inflammatory to an anti-inflammatory
Figure 3. The E2-ERα complex regulates SOCS3 and IL10 synthesis in the presence of IL4 stimulation. 
(a, b) Time-course of Socs3 (panel a) and IL10 (panel b) mRNA accumulation after IL4. RAW 264.7 were 
treated with 20 ng/ml recombinant mouse interleukin 4 (IL4, dashed line) alone or with 5 nM 17β-estradiol 
(IL4+E2, continuous line). mRNA cell content was measured by quantitative RT-PCR and data are 
expressed as $2^{-\Delta\Delta C_{t}}$ using the 36B4 transcript as an internal reference standard. Dots represent mean ± s.e.m. 
of three experiments done in triplicate, *$P < 0.05$; **$P < 0.01$; ***$P < 0.001$ by unpaired t-test. (c–h) RAW
264.7 cells were treated as described in Fig. 2. (c,e) Quantitative RT-PCR analysis of mRNAs encoding for Suppressor of cytokine signaling 3 (soCS3); data are expressed as 2^−ΔΔCt using the 36B4 transcript as internal reference standard. Bars represent the mean and s.e.m. of three separate experiments made in triplicate. ***P<0.001 by two-way ANOVA versus untreated cells. (d,f) Representative immunoblots of RAW 264.7 lysates probed with anti-bodies against SOCS3, and subjected to densitometric analysis. β-actin served as an internal loading control. Densitometry values were normalized in controls. The bars represent the mean and s.e.m. of the densitometric analysis of three separate experiments. ***P<0.001 by two-way ANOVA versus untreated cells. (g,h) Quantitative RT-PCR analysis of Interleukin 10 mRNAs (Il10); data are expressed as 2^−ΔΔCt using the 36B4 transcript as an internal reference standard. Bars represent the mean and s.e.m. of three separate experiments made in triplicate. **P<0.01 by two-way ANOVA versus untreated cells.

phenotype17,29; therefore, we next investigated the capacity of E2 to interfere with macrophage intrinsic signaling leading to the extinction of the M1 phenotype.

The reduced NF-κB life-span suggests a faster resolution of inflammation in the presence of E2 in RAW 264.7 cells. To investigate the evolution of the inflammatory process in time, we generated a reporter gene; i.e., the pNF-κB-Luc2-ires-Egfp (Supplementary Fig. S6a), which is able to gauge the state of transcriptional activity of NF-κB, the master regulator of the expression of most of the cytokines responsible for the initial phase of acute inflammation. The reporter promoter was conceived after a thorough analysis of the data in the literature and an extended experimental testing as described in the methodology section. Briefly, to identify the best NF-κB responsive element sequences, we analyzed a panel of genes involved in innate immunity (Supplementary Table S1) and thus identified two major groups of NF-κB consensus sequences. From these two groups, we selected two sequences for each group (called 1A, 1B and 2A, and 2B, Supplementary Table S2) that were particularly enriched in the promoter region of genes involved in innate immunity. Studies carried out in transient as well as in stably transfected cells using the NF-κB reporter demonstrated that activation of the reporter genes was selective, as it occurred in the presence of a number of pro-inflammatory stimuli but not the anti-inflammatory II4 (Supplementary Figs S6b–e).

Using this reporter system, we studied the influence of E2 on the course of the inflammatory process in RAW 264.7 cells transfected with the NF-κB reporter and treated with lipopolysaccharide (LPS, 1μg/mL) to trigger the inflammatory response. The production of the EGFP fluorescence was observed as early as 4h following LPS treatment. From this time point on, the intracellular fluorescence was monitored continuously by means of time-lapse microscopy (Fig. 4a). The cells expressed the fluorescent protein for 22±2h after LPS; at this time point, the fluorescence disappeared rapidly. At approximately 2h before the disappearance of the fluorescence, we observed membrane blebbing and release of fluorescent vesicles in the medium (Supplementary Fig. S7). When the RAW 264.7 cells were treated with LPS for 4h and then with 5nM E2, the duration of fluorescence expression was significantly shortened: at 8±2h, the cells ceased to express fluorescence after having undergone morphological changes similar to those observed in the cells not exposed to E2 (Supplementary Fig. S7). The accelerated loss of EGFP was not observed in cells exposed to both E2 and ICI 182,780 or to the GPR30 agonist G1 alone.

These data indicated that the hormone receptor complex was able to reduce the time of NF-κB transcriptional activity induced in response to a strong inflammatory stimulus, suggesting the ability of the hormone to shorten the pro-inflammatory phase, possibly by anticipating the resolution of inflammation. However, these findings were not in line with the prior described effect of the E2-ERα complex, which appeared to limit the ability of IL4 to induce markers of AA polarization. This led us to verify whether the termination of EGFP fluorescence in cells treated with E2 was associated with the functional changes characteristic of an accelerated loss of the M1 phenotype and conversion to AA/AD. To this aim, we investigated the time course of expression of two cytokine hallmarks for either the early phase of the pro-inflammatory process (Il1β) or the initiation of the resolution phase (Il10)30. Figure 4b shows that, in RAW 264.7 cells, 2h after LPS treatment, the content of Il1β mRNA started to accumulate to reach its maximal concentration at 7–8h (4300-fold versus T=0); from this time on, the content of cytokine mRNA slowly decreased and at 24h after LPS was still significantly higher than in untreated cells (585-fold). When cells were co-treated with LPS and E2, the changes in time of Il1β mRNA concentrations were quite different, as the max concentration was reached at 5h after LPS (3,900-fold versus T=0) and the decrease was much steeper than in the LPS-treated cells. By the 12h, Il1β mRNA content was not significantly different than untreated cells. When we focused on the trigger of the resolution phase of the inflammatory response, i.e., IL10, we observed that, in cells treated with LPS alone, the Il10 mRNA started to accumulate at approximately 8h after the inflammatory insult (60-fold versus T=0) and was 205-fold higher at 12h than at time 0. When cells were exposed to E2 and LPS together, the profile of Il10 mRNA changed significantly as the cells started to accumulate Il10 much earlier than in the previous treatment (60-fold versus T=0 at 3h), and the highest amount of Il10 mRNA (+253-fold versus T=0) was measured at 6–8h after treatment (Fig. 4c).

Further support for our findings was provided by the observed effects exerted by E2 on phagocytosis, another marker of the pro-inflammatory phenotype and a crucial event for the establishment of the
resolution phase of the inflammatory process\(^1\). Figure 4d shows the flow cytometry analysis of RAW 264.7 cells treated for 6 h with 1\(\mu\)g/ml FITC-conjugated LPS in the presence or absence of E\(_2\). The engulfment of the fluorescent compound at 6 h was significantly higher (+38%) in cells treated with LPS + E\(_2\) than in controls receiving only the pro-inflammatory stimulus. These data supported the hypothesis of a faster onset and evolution of the M1 inflammatory phase in the presence of the sex hormone.

We finally tested how, in this treatment paradigm, the presence of E\(_2\) was influencing Socs gene expression. As expected, in cells treated with LPS alone, the accumulation of Socs3 mRNA started late in the process and was clearly measurable only at 12 h after LPS (590-fold versus \(T = 0\), Fig. 4e). The presence of E\(_2\) in the medium significantly accelerated the time in which this mRNA started to accumulate (360-fold versus \(T = 0\) at 5 h after LPS + E\(_2\)). This latter effect was restricted in time, as the cells had
ceased to accumulate Socs3 mRNA 12 h after the treatment (Fig. 4e). The maximum expression of Socs3 mRNA at 6 h was consistent with prior observations on genes directly regulated by the E$_2$-ER$\alpha$ complex$^{32,33}$. Socs1 mRNA was present in the cells at a concentration much lower than Socs3 mRNA, and its production could not be clearly associated to a specific phenotype (Fig. 4f). As expected, no IL4 mRNA was synthesized by the macrophagic cell line at any time.

Discussion

The present study provided novel insights on the anti-inflammatory effects of estrogens, potentially relevant to the understanding of the role of estrogen deprivation in the evolution of pathologies characterized by a high degree of inflammation. This study, aimed at evaluating the effect of estrogens on the resolution of inflammation, indeed showed that the activation of the intracellular estrogen receptor shortened the pro-inflammatory phase and influenced the extrinsic and intrinsic programs leading to the resolution of the inflammatory phase, favoring the progression of macrophages toward the IL10-dependent AD phase, which is responsible for immunomodulation and tissue remodeling.

The mechanisms involved in estrogen-dependent progression of the inflammatory response are multiple: in the absence of stimulation by other immune cells, estrogens preferentially bind the GPR30 receptor and activate the synthesis of Arg1 mRNA through the PI3K-AKT pathway. However, when IL4R is stimulated, the intracellular concentration of ER$\alpha$ is increased, and in the presence of E$_2$, this receptor activates Socs3 expression, leading to the blockage of IL4R signaling$^{27}$. At the same time, the E$_2$-ER$\alpha$ complex facilitates STAT3 phosphorylation and the activation of the Il10 promoter, as also described in cells of different lineage$^{34,35}$. Interestingly, after the inflammatory insult, E$_2$ appeared to significantly accelerate the onset of the AD polarization by hastening IL10 synthesis and anticipating the production of IL10 and SOCS3 even in the absence of IL4. Conceivably, in this case, the ER$\alpha$ activity might be facilitated by intrinsic factors involved in the response to the inflammatory stimulus (Fig. 5).

The finding that IL4 treatment induces an increase in the expression of ER$\alpha$ (Supplementary Fig. S2) is in agreement with previous reports$^{36,37}$. In particular, the observation of a transient up-regulation of ER$\alpha$ mRNA in human macrophages following the treatment with IL4/IL13$^{37}$ suggested that this IL4 effect is well conserved in mammals. This phenomenon appeared to be functionally relevant, as the increased content of ER$\alpha$ is associated with a decrease in the production of ARG1, the main function of which is related to the inhibition of the pro-inflammatory response in the inflammatory process. The evidence of a negative effect of E$_2$ on Arg1 expression (Fig. 1a,b) in cells stimulated by IL4 is therefore quite surprising, being in apparent contrast with estrogen anti-inflammatory activity. Yet, in the inflammation process, the resolution phase is multifaceted$^{38}$; in addition to the up-regulation of the genes, which is a hallmark of the AA phenotype, such as Arg1, and necessary for the diminution of the activity of the inflammatory molecules produced, other cytokines (e.g., IL10) are generated to repair the damaged tissues in the AD phenotype. Indeed, IL10 was proposed as the marker of the AD phenotype$^{39}$ characterized by pro-healing functions with the release of angiogenetic factors, such as vascular endothelial growth factor-A (VEGFA) and transforming growth factor beta (TGF$\beta$), which are essential for tissue repair$^{40}$.

Our present results indicate that E$_2$, by activating the intracellular ER$\alpha$, shortens the time spent by macrophages in the inflammatory status and facilitates the onset of the AD phenotype. Our findings are

---

**Figure 5.** Representative scheme of the proposed mechanism.
in line with and provide mechanistic insights to the reports of an estrogen positive effect on angiogenesis and proliferation\(^1\)\(^{--}\)\(^4\)\(^{3}\) or in wound healing of chronic wounds\(^4\)\(^{4}\)\(^5\)\(^6\).

Our study may impact the understanding of the causes for the increased incidence of chronic inflammatory disorders in women after the cessation of estrogen production by the ovaries. Growing experimental evidence points to a relevant role of macrophage polarization in the progression of several pathologies linked to climacterium, the M1 pro-inflammatory state associated with the progression of osteoporosis, atherosclerosis and metabolic diseases, including diabetes\(^4\)\(^8\)\(^9\)\(^{10}\)\(^{11}\)\(^{12}\)\(^{13}\). Therefore, the ability of E\(_2\) to promote the resolution phase of inflammation may be important for the protective effects exerted by the hormone prior to menopause.

The effects of estrogens on macrophage polarization may, however, also have a negative impact on health; in fact, in young women, the incidence of pathologies driven by the AA/AD macrophages, such as scleroderma\(^6\)\(^9\) and asthma\(^6\)\(^9\), is significantly higher than in post-menopause\(^6\)\(^9\)\(^{10}\). Moreover, in selective types of cancer, tumor-associated macrophages (TAM) produce IL10 and TGF\(\beta\), contributing to the general suppression of anti-tumor activities\(^3\)\(^3\). It is well known that E\(_2\) stimulates proliferation and metastatic potential of ER\(\alpha\) positive breast cancer cells\(^4\)\(^3\), and because tumor progression and resistance to chemotherapy are associated with elevated levels of SOCS3\(^3\)\(^3\) and STAT3\(^3\)\(^3\), it is tempting to speculate that the effects of the estrogens on tumor macrophages may be involved in E\(_2\)-dependent cancer growth.

The observation that estrogen accelerates the inflammatory process, thus promoting the natural resolution of inflammation, suggests an important aspect to be fully exploited for new hormone replacement therapies. Indeed, the current trend in the generation of anti-inflammatory therapies is to create novel compounds, which may expose the organism to opportunistic infections\(^5\)\(^8\). These novel compounds would diminish the extent of chronic inflammation, thus limiting the associated tissue damage. Estrogen, via the mechanism here described, would represent an ideal anti-inflammatory treatment for women in post-menopause.

**Methods**

**Reagents.** Unless otherwise specified, chemicals were purchased from Merck (Darmstadt, Germany), and culture media and additives were obtained from Life Technologies-Invitrogen (Paisley, Scotland, United Kingdom). E\(_2\), LPS (isotype 0.111:B4), LPS-FITC (isotype 0.111:B4), LY294002, and ICI 182,780 were obtained from Sigma (Milan, Italy). Recombinant mouse IL4 was obtained from PeproTech (London, UK). AS 1517999 was obtained from Axon Medchem BV (Groningen, The Netherlands). G1 and G15 were obtained by Tocris (Bristol, UK).

**Cell cultures.** RAW 264.7 and J774A.1 cells were purchased from the American Type Culture Collection (Manassas, Va.) and grown in red-phenol free Dulbecco minimal essential medium (DMEM)-10% DCC serum (DCC; Celbio, EuroClone, Milan, Italy) supplemented with 2 g of sodium carbonate/ liter, 0.11 g of sodium pyruvate/liter, and streptomycin-penicillin (50,000 IU plus 50 mg per liter) in a humidified 5% CO\(_2\)–95% air atmosphere at 37°C.

**Real Time Reverse transcription (RT)-PCR.** RNA was extracted from RAW 264.7 cells. All samples were resuspended in TRizol reagent (Invitrogen, Milan, Italy), and RNA was isolated according to the manufacturer's instructions. One microgram of RNA was used for cDNA preparation with Moloney murine leukemia virus reverse transcriptase (Promega, Milan, Italy), as previously described\(^7\). Control reactions without the addition of the enzyme were performed for each sample. A 1:4 cDNA dilution was amplified using SYBR green chemistry. The PCR was carried out in triplicate or duplicate on a 96-well plate using GoTaq\textsuperscript{®} qPCR Master Mix Technology (Promega) according to the manufacturer's protocol using a 7900HT fast real time PCR system (Applied Biosystems, Life Technologies) with the following thermal profile: 2 min at 95°C; 40 cycles, 15 s at 95°C, 1 min at 60°C. Gene expression of target genes was assessed for Arginase-1 (Arg1; forward primer, 5′-CAGATAATGCAAGGAGTCAC-3′; reverse primer, 5′-CAGATATGCAAGGAGTCAC-3′); Esr1 (forward primer, 5′-GAGAATTTGTTGCTCCTAAAT-3′; reverse primer, 5′-GTGCGGATATGGGAAAGGATG-3′); Esr2 (forward primer, 5′-CCACACCATCC TCAATCCTAC-3′; reverse primer, 5′-CAGTAAACAGGGCAGTGA-3′); Gper1 (forward primer, 5′-CGCCACAGATCAGGACACC-3′; reverse primer, 5′-TGGGCTGCAATGGGAAATGA -3′); Il1b (forward primer, 5′-TGCCACCTTGTGACAGTGA -3′; reverse primer, 5′-GCTGCGAGATTTGAA GCTTG-3′); Il10 (forward primer, 5′-GGTTGCCAAGCCTTATCGGA-3′; reverse primer, 5′-ACCTGC TCCACTGCTTGTCT-3′); Socs3 (forward primer, 5′-GGAGATTTGCCTCCGACAC-3′; reverse primer, 5′-CACATGAGAAGGAGTCAC-3′); Tollip (forward primer, 5′-GGAGATTTGCCTCCGACAC-3′; reverse primer, 5′-CCAGTTACCTCATTCCAACATCC-3′); reverse primer, 5′-CCATCAGCACACCACCGGTCTC-3′)

**Western Blotting.** Cells were lysed in a buffer for total cellular extracts, containing 5 mM MgCl\(_2\), 20 mM HEPES (pH 7.9), 420 mM NaCl, 0.1 mM EDTA, 20% glycerol, 0.1% Triton, 5 mM β-mercaptoethanol, 0.1 mM PMSE, 10μg/ml aprotinin, and 1μg/ml leupeptin. The lysates were frozen on dry ice for 5 min...
and then thawed at 37°C for 5 min for three times. The samples were centrifuged at 13,000 rpm at 4°C for 20 min and the supernatants were collected and stored at −20°C. Protein concentration was estimated by a Bradford protein assay using BSA as the standard. Equal amounts of protein (20μg) were dissolved in Laemmli’s sample buffer, boiled for 5 min, and separated with a SDS-polyacrylamide minigel (10% and 7.5% polyacrylamide for Ym1 and CD206 detection, respectively) and then transferred overnight at 15 mA into 0.45 μm Hybond-ECL membrane (GE Healthcare, Milan, Italy). Membranes were incubated for 1 h with blocking solution containing 5% (w/v) nonfat milk in Tris-buffered saline (TBS) and subsequently probed for 1 h at room temperature with rabbit antibodies anti-mouse STAT3 (1:500; #12640, Cell Signaling Technologies, USA), pSTAT3 Tyr705 (1:500; #9138, Cell Signaling Technologies, USA), STAT6 (1:1000; #9362, Cell Signaling Technologies, USA), pSTAT6 Tyr641 (1:500; #9361, Cell Signaling Technologies, USA), ERα (1:500; SC-542, Santa Cruz Biotechnologies, USA), and SOCS3 (1:1000; #2923, Cell Signaling Technologies, USA) in incubation solution (TBS containing 5% (w/v) nonfat milk and 0.1% Tween 20). After extensive washing in TBST (TBS + 0.1% Tween 20), blots were incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG (1:2000; PI-1000, Vector Labs, USA) in incubation solution, for 1 h at room temperature. After extensive washing in TBST, immunoreactive bands were visualized using a chemiluminescence assay detection system according to the manufacturer’s instructions (Amersham™ ECL™ Western Blotting Analysis System, GE Healthcare). To ascertain that blots were loaded with equal amounts of protein lysates, they were also incubated in the presence of the antibody against β-actin protein (1:10,000; Sigma-Aldrich Corp., Milan, Italy). Subsequently, for semiquantitative analyses, the densities of the immunoreactive bands of STAT3 and pSTAT3 (86 kDa), STAT6 and pSTAT6 (110 kDa), ERα (66 kDa), SOCS3 (26 kDa), and β-actin (42 kDa) were measured by densitometric scanning of the membrane with Gel Doc™ XR Imaging Densitometer (Bio-Rad Lab, Segrate, Italy) with a specific software program (Image Studio 4.0, LI-COR Inc.).

PI3-Kinase/Akt activity assay. Modulation of the PI3-Kinase/Akt pathway has been assessed using FlowCellect™ P3K Activation Dual Detection Kit (FCCS025105, Merk-Millipore, USA) a two color flow cytometry kit designed to measure the extent of Akt phosphorylation relative to the total Akt expression in a given cell population, according to the manufacturer’s protocol. The kit includes two directly conjugated antibodies, a phospho-specific Anti-phospho-Akt (Ser473)-Alexa Fluor 488 and an Anti-Akt-Alexa Fluor 647 conjugated antibody to measure total levels of Akt. The levels of both the total and phosphorylated protein can be measured simultaneously in the same cell, resulting in a normalized and accurate measurement of Akt activation after stimulation. Briefly, at the end of the different treatments, cells were put on ice, washed three times with PBS, detached by scraping, suspended in 500 μl PBS. The cells in suspension were pipetted several times to achieve a single cell suspension. Equal volume of ice-cold Fixation Buffer has been added to the cell suspension, followed by a 20-minute incubation on ice. Cells were spun at 670 × g for 5 minutes in a 4°C centrifuge, supernatant was aspirated, and the pellet was washed twice with the Wash Buffer. Cells were permeabilized by adding 100 μl of ice-cold Permeabilization Buffer and incubated on ice for 20 minutes. Cells have been washed twice with the Wash Buffer and resuspended in 90 μl of assay buffer for staining. 5 μl of Anti-phospho-Akt-Alexa Fluor 488 and 5 μl of Anti-Akt-Alexa Fluor 647 were added to each sample. Cells were incubated for one hour on ice in the dark, washed twice and resuspended in 200 μl Assay Buffer. The median fluorescence of 10,000 cells for each sample was analyzed with a flow cytometry system (BD FACSCalibur, Becton Dickinson Biosciences, San Jose, CA, USA).

Assessment of LPS internalization. RAW 264.7 macrophage cells (approximately 2 × 10^5) were stimulated with 1 μg/ml of FITC-labeled LPS for 1 h and then treated with vehicle or 17β-estradiol (5 nM). Internalization of FITC-LPS was monitored at 3 h and 6 h by measuring the mean fluorescence of 10,000 cells for each sample with a flow cytometry system (BD FACSCalibur, Becton Dickinson Biosciences, San Jose, CA, USA); cells stimulated with unlabeled LPS served as autofluorescence reference.

Construction of the pNFκB-Luc2-ires-EGFP plasmid. Each functional cassette of the vector NFκB-Luc2-ires-EGFP was flanked with unique restriction sites to facilitate further manipulations. Each element was sequentially cloned, using standard cloning procedures, in the pEGFP-N1 (Clontech Laboratories, Inc., 1290 Terra Bella Ave. Mountain View, CA 94043 USA): 1) 641-bp DNA fragment encoding IRES element excised from pIRES vector (Clontech Laboratories, Inc., 1290 Terra Bella Ave. Mountain View, CA 94043 USA) and cloned into the SacII/AgeI restriction sites; 2) 1642-bp DNA fragment encoding luc2 excised from the pGL4.10 basic vector (Promega Corp., Madison, WI) and cloned into the the Sall/SacII restriction sites; 3) 220-bp DNA fragment of NF-κB responsive elements and TATA minimal promoter (Supplementary Fig. S6) excised from the NF-κB1.10 vector (see below) and cloned into the Asel/SalI. The construct NF-κB1 was obtained by cloning into the Asel/SalI restriction sites of pBluescript II KS+(Strategene, Agilent Technologies, Santa Clara, United States) four selected NF-κB responsive elements, synthesized by Eurofins Genomics, Ebersberg Germany. Then, the 220-bp DNA fragment of NF-κB responsive elements and TATA minimal promoter was excised and cloned into the Asel/SalI restriction sites in the pG2 basic vector (Promega Corp., Madison, WI) in order to obtain NF-κB1. The constructs NF-κB1.2, NF-κB1.3, NF-κB1.4, NF-κB1.5, NF-κB1.6 and NF-κB1.7
were derived from NF-κB1 by sequential partial digestion in order to obtain the corresponding NF-κB responsive elements arrangements.

**Transient Transfection.** RAW 264.7 cells were seeded into 24-well plates (approximately 2 × 10^5 cells per well) and cultured overnight. Transfections were carried out using the X-tremeGENE HP DNA transfection reagent (Roche), following the manufacturer's instructions. Two μg of pNF-κB-Luc2-ires-Egfp were added into 200 μl red-phenol free DMEM (Celsius, EuroClone, Milan, Italy) before mixing with 6 μl of X-tremeGENE HP DNA transfection reagent. The plasmid DNA/X-tremeGENE HP mixture was incubated at room temperature for 25 min and then added into each well of the 24-well plates. Cells were incubated for 48 hours in a humidified 5% CO2-95% air atmosphere at 37°C before treatments.

**Time Lapse fluorescence microscopy.** Culture medium was removed and substituted with 1 ml of fresh medium. Cells were treated with LPS (1 μg/ml), incubated for 4 h in a humidified 5% CO2-95% air atmosphere at 37°C, and then co-treated with vehicle, 17β-estradiol (5 nM), G1 (5 nM), ICI 182,780 (250 nM), or IL4 (20 ng/ml). Time-lapse images were recorded at 40x magnification in phase contrast and in fluorescence using a GFp filter (Excitation wavelength, 457–487 nm; emission wavelength, 502–538 nm) using a Zeiss Axiovert 200 M microscope (Carl Zeiss), beginning right after the co-treatment and ending after 24 h. 24-well plates were inserted in a cell cultivation system consisting of a heated microscope stage, incubator box, atmosphere controlling device (CTI controller 3700, Carl Zeiss) equipped with a humidifier, and a temperature controlling device (Tempcontrol 37–2 digital, Carl Zeiss). The CTI controller 3700 supplied the cultivation chamber with a heated mixture of CO2/air. The CO2 concentration and the temperature were continuously monitored and regulated by a digital feedback control algorithm, enabling a regulated dispersion of CO2 into the air stream and steady heating. Images were acquired every 30 min at each of the 24 positions with an AxioCam digital camera (Carl Zeiss) controlled by the AxioVision 4.2 software (Carl Zeiss).

**Luciferase enzymatic assay.** Supernatants containing luciferase were collected and total protein concentration was determined with a Bradford assay. Luciferase enzymatic activity in tissue extracts was then assayed with a luciferase assay buffer (470 μm luciferine, 20 mm Tricine, 0.1 mm EDTA, 1.07 mm (MgCO3)4·Mg(OH)2·6H2O, 2.67 mm MgSO4·7H2O in H2O, pH 7.8, with 33.3 mm DTT and 530 μm ATP). The light intensity was measured with a luminometer.

**Statistical analysis.** Unless otherwise stated, statistical significance was assessed by an unpaired t-test or two-way ANOVA using Bonferroni's multiple comparison post hoc tests that were performed with GraphPad Prism 5 (GraphPad Software).

**References**

1. Islander, U., Jochems, C., Lagerquist, M. K., Forsblad-d’Elia, H. & Carlsten, H. Estrogens in rheumatoid arthritis; the immune system and bone. *Mol. Cell. Endocrinol.* 335, 14–29 (2011).
2. Martin-Millan, M. & Castaneda, S. Estrogens, osteoarthritis and inflammation. *Joint Bone Spine* 80, 368–373 (2013).
3. Spence, R. D. & Voskuhl, R. R. Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration. *Front. Neuroendocrinol.* 33, 105–115 (2012).
4. Bupp, M. R. G. Sex, the ageing immune system, and chronic disease. *Cell. Immunol.* 294, 102–110 (2015).
5. Grossman, C. J. Interactions between the gonadal steroids and the immune system. *Science* 227, 257–261 (1985).
6. Olsen, N. J. & Kovacs, W. J. Gonadal steroids and immunity. *Endocrinol. Rev.* 17, 369–384 (1996).
7. Vegeto, E. et al. Estrogen prevents the lipopolysaccharide-induced inflammatory response in microglia. *J. Neurosci.* 21, 1809–1818 (2001).
8. Rettew, J. A., McCall, S. H. T. & Marriott, I. GPR30/GPER-1 mediates rapid decreases in TLR4 expression on murine macrophages. *Mol. Cell. Endocrinol.* 328, 87–92 (2010).
9. Lang, T. J. Estrogen as an immunomodulator. *Clin. Immunol.* 113, 224–230 (2004).
10. Ghisletti, S., Meda, C., Maggi, A. & Vegeto, E. 17β-Estradiol inhibits inflammatory gene expression by controlling NF-κB intracellular localization. *Mol. Cell. Biol.* 25, 2957–2968 (2005).
11. Feltly, Q. & Roy, D. Estragon, mitochondria, and growth of cancer and non-cancer cells. *J. Carcinog.* 4, 1 (2005).
12. Martingly, K. A. et al. Estradiol stimulates transcription of nuclear respiratory factor-1 and increases mitochondrial biogenesis. *Mol. Endocrinol.* 22, 669–622 (2008).
13. Reed, J. L., Dimayuga, F. O., Davies, L. M., Keller, J. N. & Bruce-Keller, A. J. Estrogen increases proteasome activity in murine microglial cells. *Neurosci. Lett.* 367, 60–65 (2004).
14. Vegeto, E., Pollio, G., Pellicciari, C. & Maggi, A. Estrogen and progesterone induction of survival of monoblastoid cells undergoing TNF-alpha-induced apoptosis. *FASEB J.* 13, 793–803 (1999).
15. Levine, E. R. Cell localization, physiology, and nongenomic actions of estrogen receptors. *J. Appl. Physiol. (1985)* 91, 1860–1867 (2001).
16. Martinez, F. O. & Gordon, S. The M1 and M2 paradigm of macrophage activation: time for reassessment. *F1000Prime Rep.* 6, 13 (2014).
17. Cohen, H. B. & Mosser, D. M. Extrinsic and intrinsic control of macrophage inflammatory responses. *J. Leukoc. Biol.* 94, 913–919 (2013).
18. Gordon, S. & Martinez, F. O. Alternative activation of macrophages: mechanism and functions. *Immunity* 32, 593–604 (2010).
19. Blaško, E. et al. Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis. *J Neuroimmunol.* 214, 67–77 (2009).
20. Thomas, P., Pang, Y., Filaardo, E. J. & Dong, J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. *Endocrinology* 146, 624–632 (2005).
in performing the experiments. The authors are supported by the European Union’s grants ERC-2012-21. Ribeiro, J. R. & Freiman, R. N. Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer. J. Biol. Chem. 276, 35684–35692 (2001).

23. Liang, X. et al. 17beta-estradiol suppresses the macrophage foam cell formation associated with SOCS3. Horm. Metab. Res. 45, 423–429 (2013).

24. Matthews, I., Almlof, T., Kietz, S., Leers, J. & Gustafsson, J. A. Estrogen receptor-alpha regulates SOCS-3 expression in human breast cancer cells. Biochem. Biophys. Res. Commun. 335, 168–174 (2005).

25. Yoshimura, A., Naka, T. & Kubo, M. SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol. 7, 454–465 (2007).

26. Whyte, C. S. et al. Suppressor of cytokine signaling (SOCS)1 is a key determinant of differential macrophage activation and function. J. Leukoc. Biol. 90, 845–854 (2011).

27. Haque, S. J., Harbor, P. C. & Williams, B. R. Identification of critical residues required for suppressor of cytokine signaling-specific regulation of interleukin-4 signaling. J. Biol. Chem. 275, 26500–26506 (2000).

28. Ciana, P. et al. Estrogen receptor alpha, a molecular switch converting transforming growth factor-alpha-mediated proliferation into differentiation in neuroblastoma cells. J. Biol. Chem. 278, 31737–31744 (2003).

29. Murray, P. J. & Wynn, T. A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 11, 723–737 (2011).

30. Berg, D. J. et al. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J. Clin. Invest. 90, 2339–2347 (1995).

31. Hallett, J. M. et al. Novel pharmacological strategies for driving inflammatory cell apoptosis and enhancing the resolution of inflammation. Trends Pharmacol. Sci. 29, 250–257 (2008).

32. Frasor, J. Estrogen receptor-alpha promotes alternative macrophage activation during cutaneous repair. J. Invest. Dermatol. 134, 2447–2457 (2014).

33. Toniolo, A. et al. Alternative Activation of Human Macrophages Is Rescued by Estrogen Treatment in Vitro and Impaired by Menopausal Status. J. Clin. Endocrinol. Metab. 100, E50–E58 (2015).

34. Buckley, C. D., Gilroy, D. W., Serhan, C. N., Stockinger, B. & Tak, P. P. The resolution of inflammation. Nat. Rev. Immunol. 13, 59–66 (2012).

35. Mantovani, A. et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25, 677–686 (2004).

36. Spiller, K. L. et al. The role of macrophage phenotype in vascularization of tissue engineering scaffolds. Biomaterials 35, 4477–4488 (2014).

37. Barnabas, O., Wang, H. & Gao, X. M. Role of estrogen in angiogenesis in cardiovascular diseases. J. Biol. Chem. 281, 168–174 (2006).

38. Evans, M. K. et al. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144, 4562–4574 (2003).

39. Dziennis, S., Jia, T., Ronneklev, O. K., Hurn, P. D. & Alkayed, N. J. Role of signal transducer and activator of transcription-3 in 17beta-estradiol mediated neuroprotection. J. Neurosci. 27, 7268–7274 (2007).

40. Bjornstrom, L. & Sjoberg, M. Signal transducers and activators of transcription as downstream targets of nongenomic estrogen receptor actions. Mol. Endocrinol. 16, 2202–2214 (2002).

41. Whyte, C. S. et al. Estrogen receptor-alpha promotes alternative macrophage activation during cutaneous repair. J. Invest. Dermatol. 134, 2447–2457 (2014).

42. Tomiolo, A. et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann. Rheum. Dis. 66, 228–234 (2007).

43. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402–408 (2001).

Acknowledgements
We thank Anna Garanzini, Giuseppe Bellinvia, Clara Meda and Monica Rebecchi for their assistance in performing the experiments. The authors are supported by the European Union’s grants ERC-2012-ADG322977-Ways and Seventh Framework Programme (FP7/2007–2013) under grant agreement no. 278850 (INMIND), and Italian grant CARIPLO (2013–0786).
Author Contributions
A.M. and A.V. conceived the study, designed experiments and wrote the paper. A.V. performed the experiments. P.C. and N.R. designed and generated the pNFκB-Luc2-ires-EGFP plasmid. A.M., A.V. and E.V. analyzed the data. All authors were participants in the discussion of results, determination conclusions and review of the manuscript.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Villa, A. et al. Estrogen accelerates the resolution of inflammation in macrophagic cells. Sci. Rep. 5, 15224; doi: 10.1038/srep15224 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/